Gilead Sciences Price Target Increased to GBX 77 by Analysts at Leerink Swann (IBT)
Leerink Swann upped their price objective on shares of Gilead Sciences (LON:IBT) from GBX 70 ($1.12) to GBX 77 ($1.23) in a research note issued on Monday, American Banking News reports. The firm currently has an “outperform” rating on the stock. Leerink Swann’s price target points to a potential downside of 73.26% from the stock’s previous close.
Shares of Gilead Sciences (LON:IBT) traded up 0.61% during mid-day trading on Monday, hitting GBX 288.00. The stock had a trading volume of 30,341 shares. Gilead Sciences has a 52 week low of GBX 194.00 and a 52 week high of GBX 292.25. The stock has a 50-day moving average of GBX 2.78 and a 200-day moving average of GBX 2.55.
IBT has been the subject of a number of other recent research reports. Analysts at Goldman Sachs Group Inc. raised their price target on shares of Gilead Sciences from GBX 59 ($0.94) to GBX 67 ($1.07) in a research note to investors on Wednesday, September 18th. Separately, analysts at Stifel Nicolaus raised their price target on shares of Gilead Sciences from GBX 65 ($1.04) to GBX 75 ($1.20) in a research note to investors on Friday, July 26th. They now have a “buy” rating on the stock. Finally, analysts at Lazard Capital Markets raised their price target on shares of Gilead Sciences from GBX 63 ($1.01) to GBX 75 ($1.20) in a research note to investors on Friday, July 26th. They now have a “buy” rating on the stock. Thirteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of GBX 69.13 ($1.10).
International Biotechnology Trust plc is an investment company. The investment objective of the Company is to achieve long-term capital growth by investing primarily in biotechnology and other life sciences companies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.